Researchers at the Lady Davis Institute for Medical Research at the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours. This breakthrough, they say, could lead to new treatments for some of the deadliest and most intractable forms of cancer; including prostate cancer, brain cancer and melanoma.
The scientists discovered a novel link between a tumour-suppressing gene known as the phosphatase and tensin homolog (PTEN) and a protein called PKR, which is known to inhibit protein synthesis. The researchers discovered that when PTEN is mutated or absent, PKR loses its inhibitory ability, and protein synthesis within the affected cells runs wild.
“This leads to high proliferation of cells with a survival advantage over normal cells,” explains Dr. Antonis E. Koromilas of the JGH Lady Davis Institute for Medical Research and McGill’s Department of Oncology. “That is a condition that facilitates tumour development.”
PTEN plays a vital role in the suppression of humans cancers by inhibiting a genetic pathway called phosphoinositide-3 kinase (PI3K). Clinicians often target PI3K with drugs when treating cancer patients, but this does not work in all cases, because not all mutant forms of PTEN interact with PI3K. In 1992, in a study published in the journal Science, Dr. Koromilas and Dr. Nahum Sonenberg of McGill University identified PKR as a potential tumour suppressor, but its association with PTEN was unsuspected at the time.
The new discovery was made by Koromilas’s graduate researcher Zineb Mounir, the study’s first author, along with colleagues in the United States. Their findings were published December 22 in the journal Science Signalling.
“Because they are not mediated by the known PI3K pathway, existing cancer treatments don’t always work on tumours with PTEN mutations,” explains Mounir.
“That’s why this discovery has such tremendous implications,” continues Koromilas.”If we start to understand how these mutants of PTEN function, we should be able to design drugs that can activate PKR, essentially switch on its protein synthesis inhibitory function.”
These treatments, Koromilas adds, don’t necessarily have to be tailored from scratch to pinpoint PKR.
“We also have learned from our work that DNA damage can actually activate the PKR pathway, and some chemotherapy treatments are known to damage DNA. So you have the option to design drugs that are specific to PKR, or you can use drugs that have a more general effect and activate this pathway almost as a side-effect.”
The study’s co-authors include Dr. Gavin Robertson of Penn State University, Dr. Maria-Magdalena Georgescu of the MD Anderson Cancer Center, and Dr. Randal Kaufman of the University of Michigan.
About the Lady Davis Institute for Medical Research at the Jewish General Hospital
The Lady Davis Institute for Medical Research (LDI), located in Montreal, Quebec, is the research arm at the Jewish General Hospital, and has strong academic ties to McGill University. With over 150 affiliated researchers, the LDI is one of the largest and most important biomedical research institutes in Quebec and all of Canada. Major breakthroughs have been made by LDI researchers in the areas of HIV/ AIDS, aging, cancer, vascular disease, epidemiology and psychosocial science, and have thereby contributed to the health and well-being of millions of patients in Montreal, across Quebec and around the world.
About the Jewish General Hospital
Now in its landmark 75th year of providing Care for All, the Jewish General Hospital has been a mainstay of superior medical care for generations of patients of all backgrounds. One of the Quebec’s largest and busiest acute-care hospitals, the JGH is committed to improving the quality of healthcare for all Quebecers in partnership with the provincial healthcare network. In this anniversary year, the Jewish General Hospital has redoubled its commitment providing patients the best possible care in a clean, safe and human-centered environment. The JGH is able to deliver these pioneering, innovative medical services by strengthening its role as a McGill University teaching hospital, by expanding and upgrading its facilities, and by pursuing cutting-edge research at the Lady Davis Institute for Medical Research. Website: jgh.ca.
About McGill University
McGill University, founded in Montreal, Quebec, in 1821, is Canada’s leading post-secondary institution. It has two campuses, 11 faculties, 10 professional schools, 300 programs of study and more than 34,000 students. McGill attracts students from more than 150 countries around the world. Almost half of McGill students claim a first language other than English – including 6,000 francophones – with more than 6,400 international students making up almost 20 per cent of the student body. Website: mcgill.ca
- Mark Shainblum, Jewish General Hospital – Tel.: 514-340-8222 Ext. 6592